Sainsbury's has donated £120,000 to a Multiple Sclerosis Society-funded study.
The Cannaboid Use in Progressive Inflammatory Brain Disease (Cupid) research aims to examine the use of a chemical compound found in cannabis plants on disability progression in people with MS.
Based on previous studies, Tetrahydrocannabinol (THC), the active ingredient of cannabis, is thought to combat nerve fibre damage and loss.
There is currently no treatment to slow down the progression of disability in MS and the Cupid study is the only phase three trial for neuro-protection in multiple sclerosis (MS).
Lee Dunster, head of research and information at the MS Society, said: "The Cupid study is based on encouraging observations from a previous clinical trial and we are hopeful the eventual outcome will mean a better quality of life for people disabled by the devastating effects of MS."
Alan Bookbinder, director of the Sainsbury Family Charitable Trusts, added that the company was "delighted" to support such "important clinical trials which could bring vital relief to so many people with MS".
According to the MS Society, approximately 85,000 people in the UK suffer from MS.
The society is currently funding approximately 50 research projects across the UK.
Please click here for advice about finding the right type of care.